Join members of our Opto Plasma B Discovery 4.0 development team for a panel discussion about our latest antibody discovery workflow.
The Beacon Quest™ is an automated 2-chip optofluidic system that allows you to run thousands of miniaturized single-cell assays in parallel and then recover cells of interest.
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.